WO2005084707A1 - うつ病、不安神経症、薬物依存症、およびこれらに類似した精神疾患治療のための有機カチオントランスポーターoct3関連分子の利用法 - Google Patents
うつ病、不安神経症、薬物依存症、およびこれらに類似した精神疾患治療のための有機カチオントランスポーターoct3関連分子の利用法 Download PDFInfo
- Publication number
- WO2005084707A1 WO2005084707A1 PCT/JP2005/003042 JP2005003042W WO2005084707A1 WO 2005084707 A1 WO2005084707 A1 WO 2005084707A1 JP 2005003042 W JP2005003042 W JP 2005003042W WO 2005084707 A1 WO2005084707 A1 WO 2005084707A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oct3
- gene
- protein
- organic cation
- compound
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 88
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 30
- 108091006764 Organic cation transporters Proteins 0.000 title claims description 289
- 238000000034 method Methods 0.000 title claims description 126
- 206010013663 drug dependence Diseases 0.000 title description 12
- 208000011117 substance-related disease Diseases 0.000 title description 12
- 230000014509 gene expression Effects 0.000 claims abstract description 154
- 101150025224 OCT3 gene Proteins 0.000 claims abstract description 120
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 66
- 238000012216 screening Methods 0.000 claims abstract description 43
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 36
- 210000004556 brain Anatomy 0.000 claims abstract description 34
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 claims abstract description 30
- 239000003112 inhibitor Substances 0.000 claims abstract description 16
- 230000000049 anti-anxiety effect Effects 0.000 claims abstract description 4
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 claims abstract 6
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims description 178
- 108090000623 proteins and genes Proteins 0.000 claims description 113
- 239000003814 drug Substances 0.000 claims description 111
- 230000000694 effects Effects 0.000 claims description 98
- 229940079593 drug Drugs 0.000 claims description 93
- 238000012360 testing method Methods 0.000 claims description 86
- 241001465754 Metazoa Species 0.000 claims description 70
- 102000004169 proteins and genes Human genes 0.000 claims description 59
- 102000039446 nucleic acids Human genes 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 57
- 150000007523 nucleic acids Chemical class 0.000 claims description 57
- 239000000935 antidepressant agent Substances 0.000 claims description 45
- 230000009471 action Effects 0.000 claims description 41
- 229940005513 antidepressants Drugs 0.000 claims description 40
- 239000000126 substance Substances 0.000 claims description 38
- 108020004414 DNA Proteins 0.000 claims description 35
- 108700008625 Reporter Genes Proteins 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 230000036961 partial effect Effects 0.000 claims description 26
- 238000003209 gene knockout Methods 0.000 claims description 24
- 230000009368 gene silencing by RNA Effects 0.000 claims description 24
- 239000003623 enhancer Substances 0.000 claims description 22
- 238000013518 transcription Methods 0.000 claims description 22
- 230000035897 transcription Effects 0.000 claims description 22
- 108090000994 Catalytic RNA Proteins 0.000 claims description 21
- 102000053642 Catalytic RNA Human genes 0.000 claims description 21
- 230000036506 anxiety Effects 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 108091092562 ribozyme Proteins 0.000 claims description 21
- 230000001105 regulatory effect Effects 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 238000005259 measurement Methods 0.000 claims description 16
- 230000006742 locomotor activity Effects 0.000 claims description 15
- 230000001419 dependent effect Effects 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 13
- 229940126585 therapeutic drug Drugs 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- 230000004853 protein function Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 150000003384 small molecules Chemical class 0.000 claims description 9
- 229940122498 Gene expression inhibitor Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 241000283984 Rodentia Species 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims 3
- 208000024891 symptom Diseases 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 86
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 230000006870 function Effects 0.000 description 29
- 102100036929 Solute carrier family 22 member 3 Human genes 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 230000032258 transport Effects 0.000 description 25
- 230000006399 behavior Effects 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 19
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 108010078791 Carrier Proteins Proteins 0.000 description 17
- 210000003734 kidney Anatomy 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 239000000021 stimulant Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 108091006735 SLC22A2 Proteins 0.000 description 12
- 102100032417 Solute carrier family 22 member 2 Human genes 0.000 description 12
- 230000001747 exhibiting effect Effects 0.000 description 11
- 210000002826 placenta Anatomy 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- YNYAYWLBAHXHLL-MRVPVSSYSA-N Normetanephrine Natural products COC1=CC([C@H](O)CN)=CC=C1O YNYAYWLBAHXHLL-MRVPVSSYSA-N 0.000 description 9
- YNYAYWLBAHXHLL-UHFFFAOYSA-N Normetanephrine Chemical compound COC1=CC(C(O)CN)=CC=C1O YNYAYWLBAHXHLL-UHFFFAOYSA-N 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 229960003638 dopamine Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 8
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 7
- 230000029142 excretion Effects 0.000 description 7
- 230000021824 exploration behavior Effects 0.000 description 7
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 7
- 229960001252 methamphetamine Drugs 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 229940076279 serotonin Drugs 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000000949 anxiolytic effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- TYFOKKOWQOKKCH-UHFFFAOYSA-N 1-propan-2-yl-2-[(1-propan-2-ylquinolin-1-ium-4-yl)methylidene]quinoline Chemical compound C1=CC2=CC=CC=C2N(C(C)C)\C1=C\C1=CC=[N+](C(C)C)C2=CC=CC=C12 TYFOKKOWQOKKCH-UHFFFAOYSA-N 0.000 description 5
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 5
- 108020005544 Antisense RNA Proteins 0.000 description 5
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003184 complementary RNA Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 229960004801 imipramine Drugs 0.000 description 5
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 150000002892 organic cations Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 4
- 101100137155 Homo sapiens POU5F1 gene Proteins 0.000 description 4
- 101100094846 Homo sapiens SLC22A3 gene Proteins 0.000 description 4
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 4
- 101100094847 Mus musculus Slc22a3 gene Proteins 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 4
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 229960001317 isoprenaline Drugs 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108700014788 member 3 solute carrier family 22 (organic cation transporter) Proteins 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000012154 norepinephrine uptake Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- IGQBMVUAVTYSTO-UHFFFAOYSA-M (2z)-2-[(3,6-dimethyl-2-phenylpyrimidin-3-ium-4-yl)methylidene]-1-ethylquinoline;chloride Chemical compound [Cl-].C1=CC2=CC=CC=C2N(CC)C1=CC([N+]=1C)=CC(C)=NC=1C1=CC=CC=C1 IGQBMVUAVTYSTO-UHFFFAOYSA-M 0.000 description 3
- AGJZCWVTGOVGBS-UHFFFAOYSA-N 1,1'-diethyl-2,2'-cyanine Chemical compound C1=CC2=CC=CC=C2N(CC)\C1=C\C1=CC=C(C=CC=C2)C2=[N+]1CC AGJZCWVTGOVGBS-UHFFFAOYSA-N 0.000 description 3
- XXCCGRRUBBGZRE-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]-2-methoxyphenol Chemical compound COC1=CC(C(O)CNC(C)C)=CC=C1O XXCCGRRUBBGZRE-UHFFFAOYSA-N 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 101100094848 Rattus norvegicus Slc22a3 gene Proteins 0.000 description 3
- 108091006734 SLC22A3 Proteins 0.000 description 3
- 101150086694 SLC22A3 gene Proteins 0.000 description 3
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 3
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 3
- 229960001066 disopyramide Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000000185 intracerebroventricular administration Methods 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- -1 neurotransmitters Chemical class 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 3
- 229960000244 procainamide Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- JVZRCNQLWOELDU-UHFFFAOYSA-O 4-phenylpyridin-1-ium Chemical compound C1=CC=CC=C1C1=CC=[NH+]C=C1 JVZRCNQLWOELDU-UHFFFAOYSA-O 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- RKMGZICTHQMBTN-UHFFFAOYSA-N 5-[1-hydroxy-2-(methylamino)ethyl]cyclohexa-2,4-diene-1,2-diol Chemical compound CNCC(O)C1=CC=C(O)C(O)C1 RKMGZICTHQMBTN-UHFFFAOYSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101100126625 Caenorhabditis elegans itr-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078140 Cation Transport Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091027874 Group I catalytic intron Proteins 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000454273 Hirashima Species 0.000 description 1
- 101001130132 Homo sapiens Protein LDOC1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- 108091006671 Ion Transporter Proteins 0.000 description 1
- JWZZKOKVBUJMES-NSHDSACASA-N L-isoprenaline Chemical compound CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-NSHDSACASA-N 0.000 description 1
- 101150051213 MAOA gene Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000004028 Octamer Transcription Factors Human genes 0.000 description 1
- 108010082496 Octamer Transcription Factors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100031705 Protein LDOC1 Human genes 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108020005543 Satellite RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710102693 Solute carrier family 22 member 3 Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000723677 Tobacco ringspot virus Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000008503 anti depressant like effect Effects 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000001353 anxiety effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 210000001172 blastoderm Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000782 cerebellar granule cell Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 210000002222 superior cervical ganglion Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 102000040811 transporter activity Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000000685 uterine artery Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Definitions
- OCT3-related molecules for the treatment of depression, anxiety, drug dependence and similar psychiatric disorders
- the present invention relates to the use of the organic cation transporter OCT3 for treating mental disorders such as depression, anxiety, and drug dependence.
- OCT organic cation transporter
- OCT3 was cloned from the rat placenta in 1998 as a transporter highly homologous to OCT1 (see Non-Patent Document 8).
- OCT3 was identified pharmacologically in the early 1990s from the gene sequence and pharmacological properties, and uptake2 or extracellular neuronal monoamine transporter (EMT) clawed from human myocardium almost simultaneously with OCT3.
- EMT extracellular neuronal monoamine transporter
- OCT3 is localized in the proximal tubule in the kidney, and is currently considered to be one of the most important transporters for excretion of cationic drugs in the kidney (see Non-Patent Document 13) .
- OCT3 is significantly different from other OCTs in substrate specificity.
- OCT3 has the transport activity of dopamine neurotoxin MPP +, noradrenaline, serotonin, dopamine, stimulants, antidepressants, etc., but it is known that these are not transported by other OCTs! /, (See Non-Patent Document 10).
- OCT3 in the brain was found only in the last cortex in in situ hybridization, and its expression in other sites was low. Therefore, OCT3 is considered to be important for controlling vomiting, appetite, and cardiovascular function! / Puru (see Non-Patent Document 14),
- OCT3 is present in glial cells and astrocytes, which are neural support cells, and plays an important role in regulating monoamine concentration in the brain (see Non-Patent Document 15).
- OCT3 may be involved in acute bronchoconstriction through suppression of norepinephrine uptake by inhaled steroids (see Non-Patent Documents 16 and 17).
- OCT3 is important for uptake of 1-methytri-4-phenylpyridinium (MPP +) in cerebellar granule cells (see Non-Patent Document 19).
- OCT3 expression is reduced by drug administration (see Non-Patent Document 20), 7) It has been shown that, in animals lacking the serotonin transporter, the expression of OCT3, which has the activity of transporting monoamines containing serotonin, is increased in some brain regions (see Non-Patent Document 21).
- kidney-derived HEK293 cells that express OCT3 / EMT that they have the transport activity of agmatine (Agmatine) that can be a parent compound of OCT3 and OCT2 dependent therapeutic agents (see Non-Patent Document 22).
- OCT3 / EMT is expressed in astrocytes, which are human neural support cells, and plays an important role in the uptake of monoamine drugs and the like (see Non-Patent Documents 24 and 25).
- OCT3 is expressed and functions in ganglion cells in the upper part of the cervix! /, (See Non-Patent Document 26)
- OCT3 / EMT is expressed on the brush border membrane side in Caco-2 cells derived from the small intestine and plays an important role in the uptake of substrates into cells (see Non-Patent Documents 27 and 28).
- OCT1 and OCT3 are involved in quantitative control of acetylcholine in human placenta (see Non-Patent Document 29),
- OCT2 and OCT3 are expressed in the choroid plexus of the brain where the blood-cerebrospinal fluid barrier exists, and OCT2 is important for choline transport at this site (see Non-Patent Document 31).
- the cation transport system is important for incorporation of agmatine in SK-MG-1 derived from human glioma, but it is highly likely that it is not via OCT3 (see Non-Patent Document 33).
- OCT3 ORCT3 in mouse
- MAO-A a monoamine metabolizing enzyme
- Rat OCT3 consists of 11 ethathons and 10 introns. Mouse OCT3 has 86% homology with human OCT3. Considering the immunohistological findings that OCT3 is located in the proximal tubule, OCT3 is thought to play an important role in excretion of cationic drugs in the kidney (see Non-Patent Document 13).
- OCT3 is expressed in rat astrocytes (see Non-Patent Document 37).
- OCT3 is identical to the extracellular monoamine transporter uptake2 and is widely distributed throughout the brain, including the hippocampus, cerebral cortex, and cerebellum (see Non-Patent Document 40).
- OCT3 / EMT is present in human glial cells (see Non-Patent Document 44).
- l, l'-Diisopropyl-2,4'-cyanine (disprocynium24) i is a potent inhibitor of CT3 / uptake2, and its intravenous administration strongly inhibits urinary excretion of monoamines (non- (See Patent Document 45),
- Uptake2 plays an important role in noradrenaline uptake into rat cardiomyocytes (see Non-Patent Document 46).
- OCT3 / EMT / uptake2 is a transporter found in rat cardiomyocytes and uses a monoamine such as dopamine, serotonin, and noradrenaline as a substrate. Since it is localized in cells other than nerve cells, it has been assumed that it is an important transporter for removing noradrenaline released during peripheral nerve stimulation.
- OCT3 may use an antidepressant as a substrate.
- antidepressants have excellent inhibitory activity on the transport of the MPT + substrate of OCT3. This is due to the fact that some of the structures of antidepressants resemble monoamines and that antidepressants have strong potency. It is derived from the fact that it is a highly cationic drug. Therefore, this drug tropism does not suggest a link between OCT3 and depression.
- the relationship between OCT3 and its medicinal properties has been aimed at, as a beta-blocker, which is a hypotensive drug.
- a beta-blocker a hypotensive agent similar in structure to monoamine, has the property of being transported to OCT3, and OCT3 is well expressed in the heart. (However, they all dropped out in the early 90's). This suggests that the expression of the transporter was consistent with the type of the substrate, and that power was also noted.
- Kekuda et al. who first closed OCT3, reported that OCT3 expression was highest in the heart and then in the lungs and kidneys, and that expression in the brain was extremely low. Later, Wu et al. Of the same group reported OCT3 expression in the brain, and several groups reported OCT3 expression in neural supporting cells such as glial cells. It has been considered that it is meaningless to evaluate the function in the center of OCT3 that is not expressed in the injured nerve V, and it has not been studied so far.
- Non-Patent Document 1 Sumio Otsuki and 2 other authors, "Molecular Mechanisms of Drug Penetration and Elimination at the Blood-Brain Barrier-Central Support Defense System", Nippon Pharmacological Magazine, 2003, Vol. -64
- Non-Patent Document 2 Hitoshi Endo, ⁇ Molecular Mechanism of Drug Transport '', Nippon Pharmacological Magazine, 2000, Vol.116, p.114-124
- Non-patent Literature 3 Koepsell H, 2nd arr., "Molecular pharmacology of organic cation transporters in kidney. J, J Membr Biol, 1999, Vol.167, p.103-117.
- Non-patent document 4 Grundemann D, 4 other authors, ⁇ Drug excretion mediated by a new prototype of polyspecific transporter. '', Nature, 1994, Vol.372, p.549-552
- Non-patent document 5 Okuda M, 4 Excellent book, ⁇ cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. '', Biochem.Biophys.Res.Commun., 1996, Vol.224, p.500-507.
- Non-patent document 6 Pritchard JB and Miller DS, "Mechanisms mediating renal secretion of organic anions and cations.”, Physiol. Rev., 1993, Vol. 73, p. 765-96
- Non-patent document 7 Gorboulev V, 9 other authors, ⁇ Cloning and characterization of two human polyspecific organic cation transporters. '', DNA Cell Biol, 1997, Vol. 16, p. 87 1-881
- Non-Patent Document 8 Kekuda R, 6 others, ⁇ Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. '', J. Biol. Chem., 1998, Vol. 273, p.15971-15979
- Non-Patent Document 9 Grundemann D, 3 other authors, ⁇ Molecular identification of the corticosterone—sensitive extraneuronal catecholamine transporter. '', Nat Neurosci, 1998, Vol.1, p.349-351.
- Non-Patent Document 10 Wu X, 7 other authors, ridentity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.J, J. Biol. Chem. ⁇ 1998, Vol.273, p.32776-32786
- Non-Patent Document 11 Inazu M, 6 other authors, ⁇ Pharmacological characterization of dopamine transport in cultured rat astrocytes. '', Life Sci., 1999, Vol. 64, p. 2239-2245
- Non-Patent Document 12 Kentaro Wakayama, Outside 3 authors, ⁇ Brain barrier excretion mechanism of 1-Mety 4-phenylpyridinium (MPP +) '', 123rd Annual Meeting of the Pharmaceutical Society of Japan, 2003, Abstracts 4, P64
- Non-Patent Document 13 Wu X, Outside 7th, ⁇ Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. '', Am J Physiol Renal Physiol. 2000 Sep, Vol.279 (3), F449 -58
- Non-Patent Document l4 Haag C, 5 others, ⁇ The localization of the extraneuronal monoamine transporter (EMT) in rat brain. '', J Neurochem. 2004 Jan, Vol.88 (2), p.291-7
- Patent Document 15 Inazu M, 2 other authors, ⁇ The role of glial monoamine transporters in the central nervous system '', Nihon Shinkei Seishin Yakurigaku Zasshi., 2003 Aug, Vol.23 (4), p.171-8
- Patent Literature lb Horvath G, 5 other authors, ⁇ Norepinephrine transport by the
- Non-Patent Document 18 Lazar A, 5 other authors, ⁇ Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3). '', J Hum Genet. ⁇ 2003, Vol.48 (5), p.226-30
- Non-Patent Document 19 Shang T, 4 other authors, ⁇ 1- Methy 4-phenylphenylidinium accumulates in cerebellar granule neurons via organic cation transporter 3. '', J Neurochem., 2003 Apr ⁇ 85 (2), p. 358—67
- Non-special reference literature 20 Kitaichi K, 7 other authors, ⁇ Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats.J, Eur J Pharmacol., 2003 Mar7, Vol.464 (l), p.39-48
- Non-special reference literature 21 Schmitt A, 7 others, ⁇ Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. '', J Neurosci Res., 2003 Marl, Vol. 71 (5), p.701-9
- Non-special reference 23 LeazerTM, and Klaassen CD., ⁇ The presence of xenobiotic transporters in rat placenta. '', Drug Metab Dispos., 2003 Feb, Vol.31 (2), p.153-67.
- Non-patent Document 26 Kritok D, 3 other authors, ⁇ Organic cation transporter mRNA and function in the rat superior cervical ganglion. '', J Physiol., 2002 Augl5,
- Non-Patent Document 27 Martel F, 3 other authors, ⁇ Uptake of (3) H-l-methy 4-phenylphenylidinium ((3) H-MPP (+)) by human intestinal Caco- 2 cells is regulated by
- Non-special reference literature 28 Martel F, 3 others, "Apical uptake of organic cations by human intestinal Caco— 2 cells: putative involvement of ASF transporters.”, Naunyn Schmiedebergs Arch Pharmacol., 2001 Jan ⁇ Vol.363 (l), p.40-9
- Non-Patent Document 29 Wessler I, 6 other authors, ⁇ Release of non- neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters. '', Br J Pharmacol., 2001 Nov ⁇ 134 (5), p. .951— 6
- Non-Patent Document 30 Shu Y, 4 other authors, ⁇ Functional characteristics and steroid
- Non-Patent Document 32 Martel F, 3 other authors, ⁇ Effect of P-glycoprotein modulators on the human extraneuronal monoamine transporter. '', Eur J Pharmacol., 2001 Jun 22, Vol.422 (l-3), p.31 -7
- Non-Patent Document 33 Molderings GJ, 3 other authors, ⁇ Agmatine and putrescine uptake in the human glioma cell line SK-MG-1. '', Naunyn Schmiedebergs Arch Pharmacol., 2001 Jun ⁇ Vol. 363 (6), p. 671-9
- Patent Document 34 Friednch A, 4 other authors, ⁇ Transport of choline and its relationship to the expression of the organic cation transporters in a rat brain microvessel endothelial cell line (RBE4). '', Biochim Biophys Acta., 2001 Jun 6, Vol.1512 (2), p.299-307
- Non-Patent Document 35 Zwart R, 4 other authors, "Impaired activity of the extraneuronal monoamine transporter system known as uptake—2 in Orct3 / Slc22a3—deficient mice.”, Mol Cell Biol., 2001 Jul, Vol. 21 (13 ), P.4188-96
- Non-Patent Document 3b Verhaagh S, 2 other authors, ⁇ The extraneuronal monoamine transporter Slc22a3 / Orct3 co-localizes with the Maoa metabolizing enzyme in mouse placenta. '' ⁇ Mech Dev. ⁇ 2001 Jan ⁇ Vol. L00 (l), p .127-30
- Non-Patent Document 37 Inazu M, 6 other authors, "Pharmacological characterization of dopamine transport in cultured rat astrocytes.”, Life Sci., 1999, Vol.64 (24), p.2239-45
- Non-Patent Document 38 Martel F, 3 other authors, ⁇ Comparison between uptake2 and rOCTl: effects of catecholamines, metanephrines and corticosterone.J, Naunyn
- Non-Patent Document 39 Dynarowicz I and Watkowski T., ⁇ The effect of oestradio 17 beta and progesterone on uptake 1, uptake2 and on release of noradrenaline in the uterine artery of ovariectomized pigs. '', Arch Vet Pol., 1993 , Vol.33 (3-4), p.249-58
- Non-Patent Document 40 Wu X, 7 other authors, ridentity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.J, J Biol Chem. ⁇ 1998 Dec4,
- Non-Patent Document 41 Martel F, 3 other authors, "Uptake of [3H] -adrenaline by freshly isolated rat hepatocytes: putative involvement of P—glycoprotein.”, J Auton Pharmacol., Feb. 1998, Vol. 18 (1 ), P.57-64
- Non-Patent Document 42 Page G, 5 other authors, "Possiole relationship between changes in [3H] DA uptake and autoxidation in rat striatal slices.”, Exp Neurol., 1998 Jul, Vol.l52 (l), p.88 -94
- Non-Patent Document 43 Kekuda R, 6 other authors, ⁇ Shi loning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.J, J Biol Chem. ⁇ 1998 Jun26, Vol. 273 (26), p.15971-9
- Non-Patent Document 44 Schomig E, 5 other authors, "The extraneuronal monoamine transporter exists in human central nervous system glia.”, Adv Pharmacol., 1998, Vol.42, p. 356-9
- Non-Patent Document 45 Graefe KH, 5 other authors, ⁇ 1,1'-Diisopropy 2,4'-cyanine
- Non-Patent Document 46 Obst OO and 2 other authors, ⁇ Characterization of catecholamine uptake2 in isolated cardiac myocytes. ", Mol Cell Biochem. ⁇ 1996 Oct—November Vol.163—164, p.181-3
- Non-Patent Document 47 Wieland A, 3 other authors, ⁇ Analysis of the gene structure of the human (SLC22A3) and murine (Slc22a3) extraneuronal monoamine transporter. '', J Neural Transm., 2000, Vol. L07 (10), p.1149-57
- Non-Patent Document 48 Lazar A, 5 other authors, "Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3) .J, J Hum Genet, 2003, Vol.48, p.226-230.
- Non-Patent Document 49 J Pharmacol Exp Ther., 2004 Jan, Vol.308 (l), p.2-9
- the present invention has been made in view of such circumstances, and an object of the present invention is to clarify the relationship between OCT3 and mental disorders such as depression, anxiety, or drug dependence.
- An object of the present invention is to provide a drug for treating a mental illness and a method for screening the drug. Means for solving the problem
- the present inventors attempted to produce a mouse in which OCT3 expression was suppressed by directly administering an antisense to OCT3 into the brain. Potential for various sites in the target site of antisense In this experiment, a sequence containing the OCT3 start codon of the target gene was used. In addition, the present inventor has established a blood-cerebrospinal fluid barrier, which is a contact point between the ventricle and blood. Focusing on the finding that OCT3 is expressed, the ventricle was selected as the brain site to which the antisense was administered.
- antisense generally adds sulfur to the phosphoric acid in the sequence to prevent degradation of the base sequence.
- Phosphorothioate is often used!
- the inventor of the present invention considered that the toxicity is actually expressed as the phosphorothioate body and that tissue necrosis often involves difficulties in experiments, and therefore, the inventor devised antisense administration into the ventricle.
- mice prepared as described above were subjected to a forced swimming test and observation of exploratory behavior. As a result, it was found that the mice exhibited an antidepressant effect due to the disappearance of the immobility during swimming, and also exhibited an anxiolytic effect due to enhanced exploratory behavior. In addition, it was confirmed that 0CT3 expression was significantly reduced in these mice.
- the present inventors further examined the effect of suppressing the expression of the 0CT3 gene and the effect of using the antidepressant in combination. As a result, they have newly found that suppressing the expression of 0CT3 enhances the action of antidepressants. That is, it was shown that a compound that regulates OCT3 expression is useful as a concomitant drug with an antidepressant.
- the present inventors have also found that a low-molecular compound targeting OCT3 actually has the same action as an antidepressant. That is, it was shown that a compound targeting OCT3 actually has a therapeutic effect on mental disorders such as depression.
- the above results show that by suppressing the expression of a single gene (OCT3), it was possible to actually produce an animal exhibiting a phenotype easily distinguishable from a wild type. It is something.
- OCT3 single gene
- the present inventors succeeded for the first time in producing an animal that can be easily distinguished from a wild-type animal by suppressing the expression of the OCT3 gene, and completed the present invention.
- the animal of the present invention is a very useful animal that actually exhibits a phenotype associated with mental disorders such as depression and anxiety.
- the above-described OCT3 gene knockout animal of the present invention is very useful for, for example, screening for a therapeutic agent for a psychiatric disorder or identifying a causative substance causing a psychiatric disorder. Since the substance obtained (identified) by the above-mentioned method (ie, the compound) can actually change (enhance or eliminate) the phenotype of the animal of the present invention, it has a therapeutic effect on mental illness, Or, it can be said that it is a substance with a very high probability of causing mental illness.
- the mouse in which the expression of OCT3 was suppressed awakened and showed an increase in drug-induced locomotor activity. That is, despite the single administration of the stimulant, the same behavior as the reverse tolerance phenomenon caused by repeated administration of the stimulant was observed.
- the present invention has succeeded in producing a mouse exhibiting a stimulant reverse resistance phenomenon, ie, exhibiting an increase in stimulant spontaneous motor activity, without repeated administration of the stimulant.
- These animals are useful for analyzing the mechanism of formation of drug dependence. Further, the above animal can be suitably used for screening a therapeutic drug for stimulant dependence.
- the present invention relates to an OCT3 knockout animal exhibiting a phenotype associated with a mental disorder such as depression, anxiety, and stimulant dependence, a drug for treating the mental disorder, and a method for screening the drug. , And more specifically,
- a drug for treating mental illness which comprises an organic cation transporter OCT3 gene expression inhibitor as an active ingredient;
- an agent for suppressing the expression of the organic cation transporter OCT3 protein which is a compound selected from the group consisting of the following (a) and (c):
- Organic cation transporter OCT3 protein function inhibitor Including, remedies for mental illness,
- a stimulant-dependent drug comprising an organic cation transporter OCT3 protein expression enhancer or a function enhancer as an active ingredient
- a method for screening a drug for treating stimulant dependence comprising the following steps (a) to (c):
- a method for screening a drug for treating stimulant dependence comprising the following steps (a) to (c):
- a method for screening a drug for treating stimulant dependence comprising the following steps (a) to (c):
- an antidepressant action enhancer comprising, as an active ingredient, an organic cation transporter OCT3 gene expression inhibitor
- an antidepressant-enhancing agent comprising an organic cation transporter OCT3 protein function inhibitor as an active ingredient
- an antidepressant action enhancer which is a compound of the following (a) or (b):
- the present invention [27] A method for preventing and / or treating a mental illness, comprising a step of administering an organic cation transporter OCT3 gene expression inhibitor or an OCT3 protein function inhibitor to an individual (eg, a patient or the like),
- (28) a method for preventing and / or treating stimulant dependence, comprising a step of administering an organic cation transporter OCT3 gene expression enhancer or OCT3 protein function enhancer to an individual (for example, a patient or the like);
- FIG. 1 is a graph showing the effect of continuous intracerebral infusion of antisense to OCT3 and the synergistic effect of antisense to low dose OCT3 and low dose antidepressant imipramine in a depression model.
- a p ⁇ 0.01 vs. solvent group
- b p ⁇ 0.01 vs. OCT3-ScrAS
- c p ⁇ 0.01 vs. (OCT—AS 0 + IMI 0)
- d p ⁇ 0.01 vs.
- OCT—AS 0 + IMI 4 IMI 4
- e p ⁇ 0.01 vs.
- OCT—AS 0.075 + IMI 0 IMI 0
- FIG. 2 is a graph showing the effect of continuous intracerebral infusion of normetanephrine relatively selectively transported to OCT3 in a depression model.
- a p ⁇ 0.01 vs. solvent group.
- FIG. 3 is a graph showing a decrease in OCT3 protein expression in rats to which antisense to OCT3 was continuously injected into the brain.
- a p ⁇ 0.01 vs. solvent group
- b p ⁇ 0.01 vs. solvent group
- FIG. 4 is a graph showing the effect of continuous antisense intracerebral injection on OCT3 in stimulant-induced locomotor activity.
- FIG. 5 is a graph showing the effect of continuous infusion of antisense to OCT3 in the brain on anxiety activity.
- the graph on the left shows the number of standing actions as a result of taking place search actions.
- the graph on the right shows the number of spontaneous movements.
- OCT3 organic cation transporter OCT3
- depression depression
- anxiety neuroopathy
- OCT3 protein a therapeutic agent for a psychiatric disorder, which comprises a substance that suppresses the expression (expression) of the OCT3 gene or OCT3 protein, or the function (activity) of the protein encoded by the OCT3 gene (OCT3 protein).
- a therapeutic drug for psychiatric disorders (a drug / pharmaceutical composition for treating psychiatric disorders), which comprises, as an active ingredient, a substance that suppresses the expression of OCT3 gene.
- OCT3 in the present invention is known to exist in various organisms.
- the OCT3 of the present invention includes OCT3 in various organisms.
- Examples of the OCT3 of the present invention include human OCT3, mouse OCT3, rat OCT3 and the like.
- the nucleotide sequences of these OCT3-encoding genes are shown in SEQ ID NOs: 1 (human), 3 (mouse), and 5 (rat), respectively.
- the amino acid sequence of the protein encoded by the nucleotide sequence is shown in SEQ ID NOs: 2 (human), 4 (mouse), and 6 (rat), respectively.
- proteins for example, have high homology (usually 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more) with the sequences described in the above sequence listing.
- a protein having the function of OCT3 (for example, the function as an organic transporter) is included in OCT3 of the present invention.
- the protein is, for example, a protein consisting of an amino acid sequence in which one or more amino acids are added, deleted, substituted, or inserted in the amino acid sequence of the protein described in any of SEQ ID NOs: 2, 4, and 6.
- the number of changed amino acids is within 30 amino acids, preferably within 10 amino acids, more preferably within 5 amino acids, and most preferably within 3 amino acids.
- examples of the "mental illness” for which a therapeutic effect is expected include depression, anxiety, mania, manic depression, schizophrenia, hyperactivity disorder (ADHD) and the like.
- the “mental disorder” in the present invention preferably, depression, anxiety, etc. can be mentioned.
- Depression is a temporary psyche that is generally characterized by sadness, loneliness, despair, and self-respect A condition or chronic mental disorder that refers to a disorder with psychomotor arrest, infrequent irritation, withdrawal from society, and plant neurological symptoms such as decreased appetite and insomnia.
- Anxiety disorder generally refers to a disease mainly caused by suddenly occurring anxiety attacks. Usually, during a seizure, palpitations are accompanied by symptoms such as tachycardia, dyspnea, dizziness, and trembling. Further, so-called “panic disorder” is also included in the aforementioned anxiety neurosis.
- OCT3 gene expression suppressors include, for example, substances that inhibit the transcription of OCT3 or the translation from the transcript.
- Preferred embodiments of the above-mentioned expression-suppressing substance of the present invention include, for example, compounds (nucleic acids) selected from the group consisting of the following (a) to (c).
- nucleic acid in the present invention means RNA or DNA.
- chemically synthesized nucleic acid analogs such as so-called PNA (peptide nucleic acid) are also included in the nucleic acid of the present invention.
- PNA is a product in which the pentasaccharide 'phosphate skeleton, which is the basic skeleton structure of nucleic acids, is replaced with a polyamide skeleton containing glycine as a unit, and has a three-dimensional structure very similar to nucleic acids.
- a method using antisense technology is well known to those skilled in the art.
- the action of the antisense nucleic acid to inhibit the expression of the target gene has several factors as follows. That is, inhibition of transcription initiation due to triplex formation, transcription inhibition by hybridization with a site where an open loop structure was locally formed by RNA polymerase, transcription inhibition by hybridization with RNA that is undergoing synthesis, intron Inhibition by splicing at spliceosome formation site, inhibition of splicing by splicosome formation site, inhibition of splicing by hybridization with mRNA, inhibition of translocation to nuclear force cytoplasm by hybridization with mRNA, cabbing site and poly (A) Splicing inhibition by hybridization with the addition site, translation initiation inhibition by hybridization with the translation initiation factor binding site, translation inhibition by hybridization with the ribosome binding site near the initiation codon, interaction with the mRNA translation region and polysome binding site Due to hybrid formation Out
- antisense nucleic acids inhibit target gene expression by inhibiting various processes such as transcription, splicing and translation (Hirashima and Inoue, Shinsei Kagaku Kenkyusho 2 Replication and Expression of Nucleic Acid IV Genes, Japan Ed. Biochemical Society, Tokyo Kagaku Dojin, 1993, 319-347.)
- the antisense nucleic acid used in the present invention may inhibit OCT3 gene expression by any of the above actions.
- designing an antisense sequence complementary to the untranslated region near the 5 ′ end of the OCT3 gene mRNA would be effective in inhibiting translation of the gene.
- a sequence complementary to the coding region or the 3 ′ untranslated region can also be used.
- a nucleic acid containing an antisense sequence of not only the translated region but also the untranslated region of the OCT3 gene is included in the antisense nucleic acid used in the present invention.
- the antisense nucleic acid used is ligated downstream of a suitable promoter, and preferably a sequence containing a transcription termination signal is ligated on the 3 'side.
- the nucleic acid thus prepared can be transformed into a desired animal by using a known method.
- the sequence of the antisense nucleic acid is preferably a sequence complementary to the endogenous OCT3 gene of the animal to be transformed or a part thereof, but is completely complementary as long as gene expression can be effectively suppressed. It is not necessary.
- the transcribed RNA has preferably 90% or more, most preferably 95% or more complementarity to the transcript of the target gene.
- the length of the antisense nucleic acid is preferably at least 15 bases and less than 25 bases. Is not necessarily limited to this length.
- the antisense of the present invention is not particularly limited.
- the 388-408th nucleotide sequence of the rat OCT3 gene obtained with GenBank accession number NM_019230, or GenBank accession number NM—0111395 Can be prepared based on the nucleotide sequence at positions 377-397 of the mouse OCT3 gene.
- an RNA complementary to the sequence of 5′-tggtcgaacgtgggcatggtg-3 ′ SEQ ID NO: 7 can be mentioned.
- Inhibition of OCT3 gene expression can be accompanied by ribozyme or ribozyme-encoding
- Ribozyme refers to an RNA molecule having catalytic activity. Enzymes that cleave RNA even in the presence of ribozymes with various activities Research focused on ribozymes as elements has enabled the design of ribozymes that cleave RNA site-specifically. Some ribozymes have a size of 400 nucleotides or more, such as the group I intron type and Ml RNA contained in RNase P, while others have an active domain of about 40 nucleotides called hammerhead type or hairpin type. (Makoto Koizumi and Eiko Otsuka, Protein Nucleic Acid Enzyme, 1990, 35, 2191.)
- the self-cleaving domain of the hammerhead ribozyme is capable of cleaving the 3 'side of C15 in the sequence G13U14C15. Its activity is based on base pairing between U14 and A9.
- U15 can also be cleaved (Koizumi, M. et al, FEBS Lett, 1988, 228, 228.).
- a ribozyme whose substrate binding site is complementary to the RNA sequence near the target site, it is possible to create a restriction-enzymatic RNA-cleaving ribozyme that recognizes the sequence UC, UU or UA in the target RNA (Koizumi, M.
- Hairpin ribozymes are also useful for the purpose of the present invention.
- This ribozyme is found, for example, on the minus strand of satellite RNA of tobacco ring spot virus (Buzayan, JM., Nature, 1986, 323, 349.). It has been shown that target-specific RNA-cleaving ribozymes can also be produced from hairpin ribozymes (Kikuchi, Y. & Sasaki, N., Nucl Acids Res, 1991, 19, 6751. 1992, 30, 112.).
- hairpin ribozymes Karlin, JM., Nature, 1986, 323, 349.
- target-specific RNA-cleaving ribozymes can also be produced from hairpin ribozymes (Kikuchi, Y. & Sasaki, N., Nucl Acids Res, 1991, 19, 6751. 1992, 30, 112.).
- RNA interference RNA interference
- siRNA RNA interference
- RNAi reduces the destruction of target gene mRNA by introducing double-stranded RNA consisting of sense RNA, which has sequence power homologous to target gene mRNA, and antisense RNA, which has complementary sequence power, into cells and the like. It is a phenomenon that can induce and suppress the expression of target genes.
- RNAi can suppress the expression of a target gene, so a simple gene knockout method can replace the complicated and inefficient method of gene disruption by homologous recombination. It has attracted attention as a method or as a method applicable to gene therapy.
- the RNA used for RNAi need not be completely identical to the OCT3 gene or a partial region of the gene, but preferably has complete homology.
- RNAi RNA interference
- a double-stranded RNA comprising a sense RNA and an antisense RNA corresponding to the partial sequence of the base sequence described in any of SEQ ID NOs: 1, 3, and 5 can be mentioned.
- DICER a member of the RNase III nuclease family
- the double-stranded RNA having the RNAi effect in the present invention also includes the double-stranded RNA before being degraded by DICER. In other words, even a long-chain RNA that does not have the RNAi effect if it has the same length is expected to be degraded into siRNA having the RNAi effect in cells, so that the present invention
- the length of double-stranded RNA is not particularly limited
- long double-stranded RNA corresponding to the full-length or almost full-length region of the OCT3 gene mRNA of the present invention is, for example, previously degraded by DICER, and the degradation product is used as a therapeutic drug for mental disorders. It is possible.
- This degradation product is expected to include a double-stranded RNA molecule (siRNA) having an RNAi effect.
- siRNA double-stranded RNA molecule
- the region on the mRNA expected to have the RNAi effect does not need to be particularly selected. That is, the region on the mRNA of the OCT3 gene of the present invention having the RNAi effect does not necessarily need to be precisely defined.
- the present invention also includes a molecule having a structure in which one end of the RNA molecule is closed, for example, an siRNA (shRNA) having a hairpin structure. That is, a single-stranded RNA molecule capable of forming a double-stranded RNA structure in the molecule is also included in the present invention.
- siRNA siRNA
- the “double-stranded RNA that can be suppressed by the RNAi effect” of the present invention is appropriately prepared by those skilled in the art based on the base sequence of the OCT3 gene of the present invention, which is the target of the double-stranded RNA.
- the double-stranded RNA of the present invention can be prepared based on the nucleotide sequence described in any one of SEQ ID NOs: 1, 3, and 5. That is, based on the base sequence described in any of SEQ ID NOs: 1, 3, and 5, an arbitrary continuous RNA region of mRNA which is a transcript of the sequence is selected, and the region corresponding to this region is selected.
- double-stranded RNA can be appropriately performed by those skilled in the art within the scope of ordinary trials. Further, those skilled in the art can also appropriately select a siRNA sequence having a stronger RNAi effect from an mRNA sequence that is a transcript of the sequence by a known method. Also, if one strand (for example, the base sequence described in any of SEQ ID NOs: 1, 3, or 5) is found out, it is easy for those skilled in the art to! (Complementary strand) base sequence. Those skilled in the art can appropriately produce siRNA using a commercially available nucleic acid synthesizer. For synthesis of a desired RNA, a general synthesis service can be used.
- a DNA (vector) capable of expressing the above-mentioned RNA of the present invention is also included in a preferred embodiment of the compound capable of suppressing the expression of the OCT3 gene of the present invention.
- the DNA (vector) capable of expressing the double-stranded RNA of the present invention includes a DNA encoding one strand of the double-stranded RNA and a DNA encoding the other strand of the double-stranded RNA, respectively. It is DNA having a structure linked to a promoter so that it can be expressed.
- the above-mentioned DNA of the present invention can be appropriately prepared by those skilled in the art by general genetic engineering techniques. More specifically, the expression vector of the present invention can be prepared by appropriately inserting a DNA encoding the RNA of the present invention into various known expression vectors.
- the expression-suppressing substance of the present invention includes, for example, a compound that suppresses OCT3 expression by binding to an OCT3 expression regulatory region (eg, a promoter region).
- the compound can be obtained, for example, using a promoter DNA fragment of OCT3 and a screening method using the binding activity to the DNA fragment as an index.
- those skilled in the art can appropriately determine whether or not the desired compound has the ability to suppress the expression of OCT3 of the present invention by a known method, for example, a reporter-assay method or the like.
- the present invention also relates to a substance that suppresses the function of the organic cation transporter OCT3 protein.
- a drug for treating a psychiatric disorder which comprises an active ingredient.
- the transport of organic cations, including neurotransmitters is inhibited and the function of neurotransmitters is increased, which is thought to be effective in treating mental illness.
- a substance that suppresses the function is considered to be effective as a therapeutic drug for mental disorders.
- Examples of the OCT3 protein function inhibitor in the present invention include the following compounds (a) and (b).
- Antibodies that bind to OCT3 protein can be prepared by methods known to those skilled in the art.
- a polyclonal antibody can be obtained, for example, as follows. Immunization of a natural OCT3 protein or a recombinant (recombinant) OCT3 protein or a partial peptide thereof expressed in a microorganism such as Escherichia coli as a fusion protein with GST or a partial peptide thereof is performed on small animals such as egrets to obtain serum.
- This is prepared by, for example, purification using ammonium sulfate precipitation, protein A, protein G columns, DEAE ion exchange chromatography, an affinity column to which OCT3 protein or a synthetic peptide is coupled, or the like.
- a monoclonal antibody for example, a small animal such as a mouse is immunized with the OCT3 protein or a partial peptide thereof, the spleen is excised from the mouse, and the spleen is crushed to separate cells. The cells are fused with a reagent such as polyethylene glycol, and a clone producing an antibody that binds to the OCT3 protein is selected from the resulting fused cells (hybridomas).
- the obtained hybridoma was transplanted into the abdominal cavity of a mouse, ascites was recovered from the mouse, and the obtained monoclonal antibody was subjected to, for example, ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography, OCT3 protein.
- it can be prepared by purification using an affinity column to which a synthetic peptide has been coupled.
- the form of the antibody of the present invention is not particularly limited as long as it binds to the OCT3 protein of the present invention.
- a human antibody a humanized antibody obtained by genetic recombination, and Antibody fragments and modified antibodies are also included.
- the OCT3 protein of the present invention used as a sensitizing antigen for obtaining an antibody is not limited with respect to the animal species from which the OCT3 protein is derived, but proteins derived from mammals such as mice and humans are preferred, and human-derived OCT3 proteins are particularly preferred. Proteins are preferred.
- a human-derived protein can be appropriately obtained by those skilled in the art using the gene sequence or the amino acid sequence disclosed herein.
- the protein used as a sensitizing antigen may be a complete protein or a partial peptide of the protein.
- the partial peptide of the protein include an amino group (N) terminal fragment and a carboxy (C) terminal fragment of the protein.
- antibody refers to an antibody that reacts with the full length or fragment of a protein.
- human lymphocytes for example, human lymphocytes infected with EB virus
- the sensitized lymphocytes can be fused with human-derived myeloma cells having permanent dividing ability, for example, U266, to obtain a hybridoma that produces a desired human antibody having a protein binding activity.
- the antibody against the OCT3 protein of the present invention inhibits the function of the OCT3 protein by binding to the OCT protein, and is expected to have, for example, a therapeutic or ameliorating effect on psychiatric disorders.
- a human antibody or a humanized antibody is preferred in order to reduce immunogenicity.
- the present invention further includes a low molecular weight substance (low molecular weight compound) that binds to the OCT3 protein as a substance that can inhibit the function of the OCT3 protein.
- the low molecular weight substance that binds to the OCT3 protein of the present invention may be a natural or artificial compound. Usually, it is a compound that can be produced or obtained by using a method known to those skilled in the art. The compound of the present invention can also be obtained by the screening method described below.
- a compound serving as a substrate of the OCT3 protein may competitively inhibit the activity of OCT3 as a transporter.
- blockers such as propranolol (therapeutic agents for heart failure and the like) are known to be transported by OCT3.
- 8 Blockers are unable to cross the blood-brain barrier, but are analogous, centrally translocating, and Substances that competitively inhibit sporter activity are expected to inhibit the function of the OCT3 protein in the brain. That is, the inhibitor is also included in the low molecular weight compound of the present invention.
- the low molecular weight compound that binds to the OCT3 protein of the above (b) includes, for example, a compound having a high affinity for OCT3.
- Specific examples of the compound include normetanephrine, which is an inactive metabolite of noradrenaline. Normethanephrine was confirmed to actually have an antidepressant action, as shown in the Examples below, and thus it can be said that the above low-molecular compound is a preferred example.
- Some of the above compounds do not target only OCT3, but have various pharmacological actions via other targets.
- 3-methoxyisoprenaline, 3-0-methyl isoprenaiine, CarteoloU,-) isoprenaline, and (-) adrenalinei have a lowering ratio
- Sar and NUii anti-swelling effects disopyramide, lidocaine, and procainamide have ⁇ arrhythmic effects
- corticosterone and estradiol has a steroid hormone-like action.
- l-methyl-4-phenylpyridinium (MPP +) is known as a dopamine neurotoxin.
- disprocynium24, decynium 22, and cyanine 863 are potent OCT3 inhibitors, but also have potent inhibitory effects on other OCT subtypes.
- an OCT3 protein mutant having a dominant negative property with respect to the OCT3 protein can be mentioned.
- "An OCT3 protein mutant having a dominant negative property with respect to the OCT3 protein” is a function that eliminates or reduces the activity of an endogenous wild-type protein by expressing a gene encoding the protein. Refers to a protein having
- the function-suppressing substance of the present invention can be appropriately obtained by the screening method of the present invention using the cation transporter activity of OCT3 as an index.
- the present invention also provides a therapeutic agent for drug awakening, comprising a substance that enhances the expression of the organic cation transporter OCT3 protein or a substance that enhances (activates) function as an active ingredient.
- a therapeutic agent for drug awakening comprising a substance that enhances the expression of the organic cation transporter OCT3 protein or a substance that enhances (activates) function as an active ingredient.
- the “enhancement of protein expression” includes enhancement of transcription from a gene, enhancement of translation from the transcription product, and the like.
- stimulants are a general term of central nervous system stimulants used to wake up drowsiness and remove fatigue, and generally refer to methamphetamine or a synthetic drug similar to methamphetamine.
- the stimulant of the present invention includes compounds other than the above-mentioned methamphetamine, and further includes stimulant analogs and the like.
- stimulants other than methamphetamine include amphetamine and MDMA.
- Examples of the stimulant-like drug include methyl phenate (drug name: Ritalin).
- Amphetamine and methamphetamine have very similar chemical structures and exhibit similar pharmacological effects.
- most stimulants whose abuse has become a problem in Japan are catalysed fuetamine, which is usually abused in the form of hydrochloride.
- Methane with methyl group Fuetamin has stronger pharmacological action.
- stimulants When stimulants are used, the heart rate, respiration, and blood pressure increase, the pupils are dilated, and appetite is decreased. Stimulants produce addiction after repeated use, and symptoms include sweating, headache, blurred vision, dizziness, insomnia, anxiety, as well as hypersensitivity to stimulants (reverse tolerance). The reverse resistance phenomenon persists for a long period of time, and stimulants are easily expressed even if taken for a long time after continuous use, and cannot be treated with existing psychiatric drugs, resulting in irreversible changes in neurological function Is interpreted as Repeated administration of stimulants in experimental animals also leads to an increase in stimulant-induced locomotor activity, which cannot be treated with existing drugs for treating psychiatric disorders.
- a substance capable of increasing spontaneous motor activity instead of a stimulant is effective as a drug for treating stimulant dependence.
- a behavior similar to the reverse tolerance phenomenon caused by repeated administration of a stimulant was observed. That is, an OCT3 protein expression enhancer or a function (activity) enhancer is awake! And is effective as a drug for treating drug dependence.
- the OCT3 gene expression inhibitor and OCT3 protein function inhibitor according to the present invention each have a therapeutic effect on psychiatric disorders such as depression and anxiety neurosis. When used in combination with a drug, it also has the effect of enhancing the action of antidepressants.
- the present invention provides an antidepressant action enhancer (an antidepressant drug concomitant) comprising, as an active ingredient, an OCT3 gene expression inhibitor or an OCT3 protein function inhibitor.
- an antidepressant action enhancer an antidepressant drug concomitant
- the present invention also relates to a pharmaceutical composition comprising an antidepressant and the antidepressant action enhancer of the present invention as active ingredients.
- Examples of the antidepressant whose action (effect) is enhanced when used in combination with the antidepressant action enhancer of the present invention include imibramine and tricyclic antidepressants having a structure similar to that of imibramine. Include classical antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin, noradrenaline reuptake inhibitors (SNRIs), and the like. Further, the present invention provides an OCT3 gene knockout non-human animal (hereinafter referred to as “OCT3 gene knockout non-human animal”) characterized in that the expression of the organic cation transporter OCT3 gene is artificially suppressed. Knockout non-human animals ”or simply“ animals ”).
- the non-human gene knockout animal of the present invention can be used, for example, for screening a drug for treating a psychiatric disorder such as depression and anxiety. It is also very useful as a disease model animal for studying the mechanisms of each of the above diseases.
- the knockout animals of the present invention also include so-called “knockdown animals” in which gene expression is suppressed by the action of antisense RNA or siRNA.
- the expression of the OCT3 gene is artificially suppressed includes, for example, (l) a gene such as nucleotide insertion, deletion, or substitution in one or both of the OCT3 gene pairs.
- a state in which the expression of the gene is suppressed by having a mutation includes, and (2) a state in which the expression of the gene is suppressed by the action of the nucleic acid of the present invention (eg, antisense RNA or siRNA). be able to.
- suppression in the present invention includes the case where the expression of the OCT3 gene is completely suppressed and the expression level of the OCT3 in the animal of the present invention as compared with the expression level of the OCT3 gene in the wild-type animal. If significantly reduced, then included.
- the above (1) includes a case where the expression of only one gene of the OCT3 gene pair is suppressed.
- the site where the gene mutation is present in the present invention is not particularly limited as long as expression of the gene is suppressed, and examples thereof include an exon site and a promoter site.
- the gene knockout animal of the present invention can be prepared by those skilled in the art by generally known genetic engineering techniques.
- a gene knockout mouse can be prepared as follows. First, a DNA containing the exon portion of the OCT3 gene of the present invention is isolated from the mouse, and a suitable marker gene is inserted into this DNA fragment to construct a targeting vector. This targeting vector is introduced into a mouse ES cell line by electoporation or the like, and a cell line in which homologous recombination has occurred is selected.
- the marker gene to be inserted includes an antibiotic resistance gene such as a neomycin resistance gene. Is preferred.
- a cell line in which homologous recombination has occurred can be selected only by culturing in a medium containing the antibiotic.
- a thymidine kinase gene or the like can be linked to a targeting vector.
- a homologous recombinant is assayed by PCR and Southern blot to improve the efficiency of obtaining a cell line in which one of the gene pairs of the gene of the present invention is inactivated.
- chimera may be prepared using a plurality of clones in addition to the homologous recombination site, since there is a risk of unknown gene disruption due to gene insertion. Preferred ⁇ .
- the obtained ES cell line is injected into mouse blastoderm to obtain a chimeric mouse.
- a mouse obtained by inactivating one of the gene pairs of the OCT3 gene of the present invention can be obtained.
- a mouse in which both of the gene pair of the gene of the present invention are inactivated can be obtained.
- Gene modification can also be performed in animals other than mice in which ES cells have been established by the same method.
- the knockout animal of the present invention is preferably characterized in that expression of the OCT3 gene is suppressed by introducing the nucleic acid of the present invention into a non-human animal, whereby knockout (knockdown) is performed. ) Animals.
- the above-mentioned knockdown animal can also be produced by introducing a vector having a structure capable of expressing the nucleic acid (antisense RNA or siRNA) of the present invention into a non-human animal.
- a preferred embodiment of the present production method is a method for producing a knockout non-human animal, which comprises a step of administering the nucleic acid of the present invention into the brain of the animal of the present invention. More specifically, for example, a method comprising a step of administering an antisense nucleic acid against a transcript of the OCT gene or a part thereof into the brain of the animal of the present invention, preferably into the ventricle. Administration can be performed, for example, by the method described in the Examples.
- the antisense nucleic acid of the present invention is not particularly limited, but for example, those designed as follows are preferable. (1) Set the start codon of the target gene OCT3 Antisense sequence. (2) The optimal length of antisense is 18-25mer. (3) The upstream of the initiation codon should not be taken too long because there is a possibility that the transcription regulatory region may be forced. (4) Avoid designs in which the antisense itself is a monomer (a single strand binds itself) or a dimer (a bond between two antisenses).
- the type of the knockout animal of the present invention is not particularly limited as long as it is a non-human animal, but is usually a mammal, and preferably a primate. More specifically, the animal of the present invention is preferably a rodent (eg, rodent) such as a mouse, a rat, or a hamster, or a monkey, and more preferably a mouse or a monkey.
- rodent eg, rodent
- the knockout non-human animal of the present invention is not particularly limited, but the expression of the OCT3 gene is suppressed by the action of any of the following nucleic acids (a) to (c): Being an animal.
- the OCT3 gene knockout (knockdown) non-human animal of the present invention is an animal characterized by exhibiting a phenotype associated with a mental disorder such as depression, anxiety, wakefulness, and drug dependence. More specifically, the animal of the present invention is, for example, a gene knockout non-human animal characterized by exhibiting at least one of the following phenotypes (a) to (c).
- the above-mentioned animal of the present invention is very useful for, for example, screening for a therapeutic agent for a mental disease, identification of a causative substance causing a mental disease, and analysis of a mechanism of drug dependence formation.
- the present invention also provides a method for screening a drug for treating a mental disorder (eg, depression, anxiety, etc.) or treating a stimulant-dependent drug, and a method for identifying a causative compound of a mental disorder.
- a drug for treatment includes a concomitant drug with a therapeutic drug (therapeutic drug action enhancer).
- a concomitant drug for example, a therapeutic agent action enhancer
- psychiatric disorders for example, depression, anxiety, etc.
- stimulant dependence for example, depression, anxiety, etc.
- the screening method of the present invention is preferred! /
- the method is a method using binding to an organic cation transporter OCT3 protein or a partial peptide thereof as an index.
- a compound that binds to the OCT3 protein or a partial peptide thereof is expected to have an effect of inhibiting the function of the OCT3 protein.
- the above method of the present invention is a method including the following steps (a) to (c).
- an OCT3 protein or a partial peptide thereof is The test compound is brought into contact.
- the OCT3 protein or a partial peptide thereof may be, for example, a purified form, an intracellularly or extracellularly expressed form, or an affinity form of the OCT3 protein or a partial peptide thereof according to an index for detecting binding to a test compound. It may be in a form bound to a tea column.
- the test compound used in this method can be appropriately labeled and used as necessary. Examples of the label include a radiolabel, a fluorescent label and the like.
- the binding activity between the OCT3 protein or its partial peptide and the test compound is measured in the following manner.
- the binding between the OCT3 protein or its partial peptide and the test compound can be detected, for example, by labeling the test compound bound to the OCT3 protein or its partial peptide.
- a change in the activity of the OCT3 protein caused by the binding of the test compound to the OCT3 protein or its partial peptide expressed in or outside the cell can be detected as an index.
- test compound that binds to the OCT3 protein or a partial peptide thereof is selected in the following steps.
- the compound selected (obtained) by this method is expected to have an OCT3 protein inhibitory effect.
- a drug for treating a mental disease for example, a therapeutic drug or a therapeutic drug action enhancer
- a mental disease for example, a therapeutic drug or a therapeutic drug action enhancer
- Another embodiment of the screening method of the present invention is a method using the OCT3 gene expression level as an index.
- Compounds that decrease the expression level of the OCT3 gene are expected to be drugs for treating mental illness.
- compounds that increase the expression level of the OCT3 gene are expected to be drugs for the treatment of stimulant dependence.
- the method of the present invention is, for example, a method for screening a drug for treating a psychiatric disorder, comprising the following steps (a) to (c).
- the above-mentioned method of the present invention is, for example, a method for screening a drug for treating a stimulant-dependent disease, comprising the following steps (a) to (c).
- a test compound is brought into contact with cells expressing the OCT3 gene.
- the origin of the "cells” used includes cells derived from humans, mice, rats, and the like, but is not limited to cells derived from these.
- cells expressing the endogenous OCT3 gene or cells into which the exogenous OCT3 gene has been introduced and expressing the gene can be used.
- Cells expressing an exogenous OCT3 gene can be usually prepared by introducing an expression vector into which an OCT3 gene has been inserted into a host cell.
- the expression vector can be prepared by a general genetic technology.
- test compound used in the present method is not particularly limited.
- a single compound such as a natural compound, an organic compound, an inorganic compound, a protein, or a peptide, and an expression product of a compound library or a gene library , A cell extract, a cell culture supernatant, a fermented microorganism product, a marine organism extract, a plant extract, and the like.
- the "contact" of a test compound with cells expressing the OCT3 gene is usually performed by adding the test compound to a culture solution of cells expressing the OCT3 gene, but is not limited to this method.
- the test compound is a protein or the like
- “contact” can be performed by introducing a DNA vector expressing the protein into the cell.
- the expression level of the OCT3 gene is then measured.
- expression of a gene includes both transcription and translation.
- the measurement of the expression level of the gene can be performed by a method known to those skilled in the art.
- the cellular ability to express the OCT3 gene is also extracted from mRNA according to a standard method, and the transcription level of the gene is measured by performing Northern hybridization or RT-PCR using the mRNA as a type II. Settings can be made.
- the protein fraction can be collected from cells expressing the OCT3 gene, and the expression level of the OCT3 protein can be detected by electrophoresis such as SDS-PAGE to measure the translation level of the gene.
- the level of translation of the gene can be measured by detecting the expression of the OCT3 protein by detecting the expression of the protein by performing a Western blotting method using an antibody against the protein.
- the antibody used for detecting the OCT3 protein is not particularly limited as long as it is a detectable antibody. For example, both a monoclonal antibody and a polyclonal antibody can be used.
- a compound that decreases the expression level or a compound that increases the expression level is selected as compared to the case where the test compound is not contacted (comparison).
- Another embodiment of the screening method of the present invention is a method of identifying a compound that decreases or increases the expression level of the organic cation transporter-OCT3 gene of the present invention using the expression of the reporter gene as an index. .
- the above-mentioned method of the present invention is, for example, a method for screening a drug for treating a mental disease, comprising the following steps (a) to (c).
- the above method of the present invention is, for example, a method for screening a drug for treating a stimulant-dependent disease, comprising the following steps (a) to (c).
- a test compound is contacted with a cell or cell extract containing DNA having a structure in which a transcription regulatory region of the OCT3 gene and a reporter gene are functionally linked.
- “functionally linked” means that the transcription factor binds to the transcription control region of the OCT3 gene, so that the expression of the reporter gene is induced by the transcription factor binding to the transcription control region of the OCT3 gene. And are combined. Therefore, even when the reporter gene is linked to another gene and forms a fusion protein with another gene product, the fusion factor is linked to the transcription regulatory region of the OCT3 gene by the transcription factor. If the expression of the protein is induced, it is included in the meaning of the above “functionally linked”. Based on the cDNA base sequence of the OCT3 gene, those skilled in the art can obtain the transcription regulatory region of the OCT3 gene present in the genome by a known method.
- the reporter gene used in this method is not particularly limited as long as its expression can be detected. Examples include the CAT gene, lacZ gene, luciferase gene, and GFP gene.
- Cells containing DNA having a structure in which the transcription control region of the OCT3 gene and the reporter gene are functionally linked include, for example, cells into which a vector having such a structure inserted is introduced. Such a vector can be prepared by a method well known to those skilled in the art. The vector can be introduced into cells by a general method, for example, a calcium phosphate precipitation method, an electric pulse perforation method, a ribofuethamine method, a microinjection method, or the like.
- Cells containing DNA having a structure in which the transcription regulatory region of the OCT3 gene and the reporter gene are functionally linked also include cells in which the structure is inserted into a chromosome. Insertion of a DNA structure into a chromosome can be performed by a method generally used by those skilled in the art, for example, a gene transfer method utilizing homologous recombination.
- the "cell extract containing DNA having a structure in which the transcription regulatory region of the OCT3 gene and the reporter gene are functionally linked” refers to, for example, a cell extract contained in a commercially available in vitro transcription / translation kit.
- the transcriptional regulatory region of the OCT3 gene and the reporter gene are functional To which DNA having a structure bound to the DNA is added.
- the "contacting" in the present method includes adding a test compound to a culture solution of "a cell containing a DNA having a structure in which a transcription regulatory region of the OCT3 gene is functionally linked to a reporter gene", or It can be carried out by adding a test compound to the above-mentioned commercially available cell extract containing DNA.
- the test compound is a protein
- the test can be carried out by introducing a DNA vector expressing the protein into the cells.
- the expression level of the reporter gene is then measured.
- the expression level of the reporter gene can be measured by a method known to those skilled in the art according to the type of the reporter gene.
- the expression level of the reporter gene can be measured by detecting acetylamyl chloram phenochol by the gene product.
- the reporter gene is the lacZ gene
- the color of the dye compound is detected by the catalytic action of the gene expression product
- the reporter gene is the luciferase gene
- the fluorescence is due to the catalytic action of the gene expression product.
- the expression level of the reporter gene can be measured by detecting the fluorescence of the compound and, if it is a GFP gene, by detecting the fluorescence of the GFP protein.
- the measured expression level of the reporter gene is then decreased (suppressed) or increased (increased) as compared to the case where the expression level is measured in the absence of the test compound.
- Select compounds A compound that decreases (suppresses) is a drug for the treatment of mental illness, and a compound that increases (increases) is a drug for the treatment of stimulant dependence.
- Another embodiment of the screening method of the present invention is a method using the activity of the organic cation transporter OCT3 protein as an indicator.
- the method of the present invention is, for example, a method for screening a drug for treating a psychiatric disorder, comprising the following steps (a) to (c).
- the method of the present invention is, for example, a method for screening a drug for treating a stimulant-dependent disease, comprising the following steps (a) to (c).
- test compound is brought into contact with an OCT3 protein or a cell or a cell extract expressing the protein.
- OCT3 protein activity includes, for example, the transport activity of monoamines and their related drugs. More specifically, transport activities of dopamine, serotonin, noradrenaline, dopamine neurotoxin MPP +, stimulants and the like can be mentioned. Measurement of these activities can be performed by a method known to those skilled in the art.
- the regulation of the transport activity of the above-mentioned monoamine and its related drug is carried out by labeling the above-mentioned substance which can be transported by OCT3 with a radioisotope, exposing it to a test compound and OCT3-expressing cells, and It can be evaluated later by comparing the radioactivity of the radiolabeled substance incorporated into the cells. Even if radiolabeling is not possible, it is possible to evaluate the transport activity of the above-mentioned monoamine and its related drugs using a measuring instrument such as high-performance liquid chromatography (HPLC) if the intracellular concentration of the substance is sufficient. It is.
- HPLC high-performance liquid chromatography
- a compound that reduces (suppresses) or increases (increases) the activity of the protein as compared with the case where the measurement is performed in the absence of the test compound is selected.
- a compound that decreases (suppresses) becomes a drug for the treatment of mental illness, while a compound that increases (increases) becomes a drug for treating drug dependence.
- the present invention also provides a method for identifying a causative compound of a psychiatric disorder using the above-mentioned animal of the present invention.
- the present invention also relates to a screening method for a drug (stimulant drug) for treating stimulant dependence.
- the method of the present invention is, for example, a method for identifying a causative compound of a mental disease, comprising the following steps (a) to (c).
- the above-mentioned method of the present invention is a method for identifying a causative compound of a psychiatric disorder, using a behavior depending on the phenotype of the animal of the present invention as an index.
- test compound is administered to the above-described gene knockout non-human animal.
- the test compound can be administered by oral or parenteral administration, preferably by parenteral administration.
- parenteral administration preferably by parenteral administration.
- injection, nasal, pulmonary, transdermal Dosage forms and the like can be mentioned.
- the injection form include systemic or local administration, for example, by intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection and the like.
- a viral vector such as a retrovirus, an adenovirus, or a Sendai virus, or a non-viral vector such as a ribosome
- a non-viral vector such as a ribosome
- the administration method include an in vivo method and an ex vivo method.
- the phenotype of a non-human animal in which the OCT gene has been knocked out is, for example, preferably one that exhibits the above-mentioned (a) antidepressant-like action or (c) anxiolytic action.
- a compound that eliminates these phenotype-dependent behaviors is further selected.
- the selected compound is determined to be a causative compound of the mental illness. This These identified compounds causing mental disorders are useful, for example, as reagents for elucidating the mechanism of mental disorders.
- the method of the present invention is, for example, a method for screening a drug for treating stimulant dependence, which comprises the following steps (a) to (c).
- the compound selected in the above step (c) is determined to be a drug for the treatment of stimulant dependence.
- the drug of the present invention or the therapeutic compound is used as a drug
- the drug or compound itself is directly administered to a patient, and the drug or compound itself is used as a pharmaceutical composition formulated by a known pharmaceutical method. It is also possible to administer.
- the drug or compound of the present invention can be obtained, for example, by mixing with a pharmacologically acceptable carrier (excipient, binder, disintegrant, flavoring agent, flavoring agent, emulsifier, diluent, solubilizing agent, etc.).
- compositions or tablets, pills, powders, granules, capsules, troches, syrups, solutions, emulsions, suspensions, injections (solutions, suspensions, etc.), suppositories, inhalants It can be in a form suitable for oral or parenteral use as a preparation such as a skin absorbent, eye drops, eye ointment and the like.
- the present invention also relates to a method for treating or preventing a psychiatric disorder, which comprises administering the therapeutic agent for a psychiatric disorder or the antidepressant-enhancing agent of the present invention to an individual (eg, a patient or the like).
- a method for treating or preventing stimulant dependence which comprises administering the therapeutic agent for stimulant dependence of the present invention to an individual (eg, a patient or the like).
- the individual in the treatment method of the present invention usually refers to a patient with the above-mentioned disease, and is not particularly limited, but is preferably a human.
- administration to a patient can be performed by methods known to those skilled in the art, such as, for example, intraarterial injection, intravenous injection, and subcutaneous injection.
- the dose varies depending on the weight and age of the patient, the administration method, and the like, but those skilled in the art can appropriately select an appropriate dose.
- the compound can be encoded by DNA, the DNA is treated with a gene. Incorporation into a therapeutic vector to perform gene therapy is also conceivable.
- Examples of the vector for gene therapy include a viral vector such as a retrovirus vector, an adenovirus vector, an adeno-associated virus vector, and a non-viral vector such as a ribosome.
- the target DNA can be administered to a patient by an ex vivo method or an in vivo method using the vector.
- the present invention further relates to the use of an OCT3 expression inhibitor or a function inhibitor in the production of a therapeutic agent for psychiatric disorders or an antidepressant drug enhancer.
- mice Male ddY mice were used in the experiment. Mice bred for 3 days or more after purchase
- OCT3 antisense generated from the OCT3 gene sequence was continuously injected into the ventricle using an osmotic pump based on a previous report (J. Chem. Neuroanat. 2000 20: 375-87). .
- Ringer's solution which is a solvent for antisense (solvent group)
- a group that injects a cDNA sequence that has the same base as antisense and has no homology to the existing gene was also prepared.
- One week after injection was again swam in the beaker for 300 seconds and the immobility time was measured.
- the antidepressant imipramine was administered intraperitoneally 30 minutes before the start of the test.
- mice Male ddY mice were used in the experiment. Mice bred for 3 days or more after purchase were divided into two groups, and one group contained antisense (OCT3 antisense) prepared from the OCT3 gene sequence in a previous report (J. Chem. Neuroanat. 2000 20: 375-87). Based on this, it was continuously injected into the ventricle using an osmotic pump. Another group performed sham operations. One week after the injection, the stimulant methamphetamine (1 mg / kg) was administered, and the stimulant-induced locomotor activity was measured.
- OCT3 antisense antisense prepared from the OCT3 gene sequence in a previous report (J. Chem. Neuroanat. 2000 20: 375-87). Based on this, it was continuously injected into the ventricle using an osmotic pump. Another group performed sham operations. One week after the injection, the stimulant methamphetamine (1 mg / kg) was administered, and the stimulant-induced locomotor activity was measured
- mice injected with OCT3 antisense showed waking and increased drug-induced spontaneous locomotor activity. Behavior similar to the reverse tolerance phenomenon was observed (Fig. 4).
- the intracerebroventricular injection of OCT3 antisense (1-2 weeks) reduced the brain OCT3 expression by about 30% compared to the sham operation group. This is almost the same as the previously reported antisense intraventricular injection. It was the effect of.
- mice Male ddY mice were used for the experiment. Mice bred for 3 days or more after purchase were divided into two groups, and one group contained antisense (OCT3 antisense) prepared from the OCT3 gene sequence in a previous report (J. Chem. Neuroanat. 2000 20: 375-87). Based on this, it was continuously injected into the ventricle using an osmotic pump. Another group performed sham operations. One week after injection, the animals were placed in new wide cages and their relocation and standing behaviors were measured for 90 minutes.
- OCT3 antisense prepared from the OCT3 gene sequence in a previous report (J. Chem. Neuroanat. 2000 20: 375-87). Based on this, it was continuously injected into the ventricle using an osmotic pump. Another group performed sham operations. One week after injection, the animals were placed in new wide cages and their relocation and standing behaviors were measured for 90 minutes.
- the OCT3 gene knockout animal created for the first time by the present inventors exhibits a phenotype associated with a mental illness that is easily distinguishable from a wild-type animal.
- a compound related to a psychiatric disorder such as depression, anxiety neurosis, and drug dependence, or a therapeutic drug for the disease.
- the compound obtained by the screening method of the present invention is expected to be a highly effective drug because it actually has the effect of causing a change in phenotype at the animal level.
- the above-mentioned animal of the present invention is extremely useful as a pathological model animal for elucidating the mechanisms of various mental illnesses.
- the antidepressant effect of the mouse exhibiting the antidepressant phenotype of the present invention is dramatic (for example, it swims for 5 minutes or more in a forced swimming test) and is extremely useful as a disease model animal.
- the substance of the present invention that suppresses OCT3 expression has the effect of enhancing the action of an antidepressant. It was found that there was. That is, the substance functions as an antidepressant action enhancer, and is very useful as a concomitant drug with existing antidepressants. Even in the case of a low dose in which the existing antidepressant drug is not sufficiently effective, it is possible to exert an antidepressant effect by using the antidepressant action enhancer of the present invention in combination. is there.
- a combined use of the antidepressant drug-enhancing effect of the present invention provides a low dose that reduces the side effect.
- a desired effect can be exhibited.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Environmental Sciences (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Food Science & Technology (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510650A JPWO2005084707A1 (ja) | 2004-03-09 | 2005-02-24 | うつ病、不安神経症、薬物依存症、およびこれらに類似した精神疾患治療のための有機カチオントランスポーターoct3関連分子の利用法 |
EP05719492A EP1736172A4 (en) | 2004-03-09 | 2005-02-24 | METHOD OF USING ORGANIC CATION TRANSPORTER OCT3 MOLECULAR FOR THE TREATMENT OF MENTAL DISEASES SUCH AS DEPRESSION, ANIMAL FEARNESS, DRUG DEPENDENCE, AND THE SAME |
US10/592,154 US20070136828A1 (en) | 2004-03-09 | 2006-02-24 | Methods of using molecules related to organic cation transporter 3 (oct3) for treating depression, anxiety neuroses, drug dependencies, and other similar mental disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-065051 | 2004-03-09 | ||
JP2004065051 | 2004-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005084707A1 true WO2005084707A1 (ja) | 2005-09-15 |
Family
ID=34918215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003042 WO2005084707A1 (ja) | 2004-03-09 | 2005-02-24 | うつ病、不安神経症、薬物依存症、およびこれらに類似した精神疾患治療のための有機カチオントランスポーターoct3関連分子の利用法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070136828A1 (ja) |
EP (1) | EP1736172A4 (ja) |
JP (1) | JPWO2005084707A1 (ja) |
CN (1) | CN1964741A (ja) |
WO (1) | WO2005084707A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014103801A1 (ja) | 2012-12-28 | 2014-07-03 | 株式会社新日本科学 | イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤 |
WO2015002150A1 (ja) | 2013-07-03 | 2015-01-08 | 株式会社新日本科学 | 新規化合物,有機カチオントランスポーター3の検出剤及び活性阻害剤 |
JP2017501995A (ja) * | 2013-12-06 | 2017-01-19 | ノビミューン エスアー | 抗tlr4抗体およびその使用方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090221552A1 (en) * | 2006-02-28 | 2009-09-03 | The Mclean Hospital Corporation | Methods for the Treatment of ADHD and Related Disorders |
WO2009134877A2 (en) * | 2008-04-29 | 2009-11-05 | Board Of Regents, The University Of Texas System | Therapeutics for treatment resistant mental disorders |
CN102181449B (zh) * | 2011-03-06 | 2013-04-10 | 浙江大学 | 表达人有机阳离子转运体1的细胞模型构建及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036634A1 (fr) * | 1999-11-18 | 2001-05-25 | Center For Advanced Science And Technology Incubation, Ltd. | Nouveaux recepteurs couples a la proteine g, genes desdits recepteurs et leur utilisation |
JP2002233383A (ja) * | 2001-02-09 | 2002-08-20 | Locomogene Inc | ニューロトニンおよびその利用 |
WO2003018804A1 (fr) * | 2001-08-27 | 2003-03-06 | Japan Science And Technology Agency | Proteines pouvant commander la migration cellulaire et la mort cellulaire |
WO2003039462A2 (en) * | 2001-11-02 | 2003-05-15 | Tanox, Inc. | B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277565B1 (en) * | 1997-11-06 | 2001-08-21 | Millennium Pharmaceuticals, Inc. | OCT-3 gene encoding transporter-like molecules |
US6403645B2 (en) * | 2000-03-16 | 2002-06-11 | President And Fellows Of Harvard College | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them |
-
2005
- 2005-02-24 CN CNA2005800147433A patent/CN1964741A/zh active Pending
- 2005-02-24 EP EP05719492A patent/EP1736172A4/en not_active Withdrawn
- 2005-02-24 WO PCT/JP2005/003042 patent/WO2005084707A1/ja active Application Filing
- 2005-02-24 JP JP2006510650A patent/JPWO2005084707A1/ja not_active Withdrawn
-
2006
- 2006-02-24 US US10/592,154 patent/US20070136828A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036634A1 (fr) * | 1999-11-18 | 2001-05-25 | Center For Advanced Science And Technology Incubation, Ltd. | Nouveaux recepteurs couples a la proteine g, genes desdits recepteurs et leur utilisation |
JP2002233383A (ja) * | 2001-02-09 | 2002-08-20 | Locomogene Inc | ニューロトニンおよびその利用 |
WO2003018804A1 (fr) * | 2001-08-27 | 2003-03-06 | Japan Science And Technology Agency | Proteines pouvant commander la migration cellulaire et la mort cellulaire |
WO2003039462A2 (en) * | 2001-11-02 | 2003-05-15 | Tanox, Inc. | B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
Non-Patent Citations (7)
Title |
---|
KEKUDA R. ET AL: "Cloning and Functional Characterization of a Potential-sensitive, Polyspecific Organic Cation Transporter (OCT3) Most Abundantly Expressed in Placenta", J. BIOL.CHEM., vol. 273, no. 26, 1998, pages 15971 - 15979, XP002996655 * |
KITAICHI K. ET AL: "Gyakutaisei Dobutsu Model ni okeru Methamphetamine no Seitainai Kyodo Henka", JPN. J. NEUROPSYCHOPHARMACOL., vol. 21, 2001, pages 133 - 144, XP002996652 * |
NUMACHI Y. ET AL: "Kakuseizai no Tainai Dotai to Nonai Bunpu", CLIN. NEUROSCI., vol. 22, no. 6, 2004, pages 693 - 695, XP002996656 * |
OTSUKI S. ET AL: "Nokanmon o Kaishita 1-methyl-4-phenylpyridinium (MPP+) Haishutsu Kiko", JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, vol. 63, no. 1, 2003, pages 173, XP002996654 * |
See also references of EP1736172A4 * |
SHANG T. ET AL: "1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3", J. NEUROCHEM., vol. 85, 2003, pages 358 - 367, XP002996653 * |
VIALOU V. ET AL: "Toward a physiological role for organic cation transporters in the central nervous system", RECENT RES. DEVEL. NEUROCHEM., vol. 6, 2003, pages 53 - 63, XP002996651 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014103801A1 (ja) | 2012-12-28 | 2014-07-03 | 株式会社新日本科学 | イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤 |
US10149840B2 (en) | 2012-12-28 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent |
WO2015002150A1 (ja) | 2013-07-03 | 2015-01-08 | 株式会社新日本科学 | 新規化合物,有機カチオントランスポーター3の検出剤及び活性阻害剤 |
JPWO2015002150A1 (ja) * | 2013-07-03 | 2017-02-23 | 株式会社新日本科学 | 新規化合物,有機カチオントランスポーター3の検出剤及び活性阻害剤 |
US9745274B2 (en) | 2013-07-03 | 2017-08-29 | Shin Nippon Biomedical Laboratories, Ltd. | Compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor |
JP2017501995A (ja) * | 2013-12-06 | 2017-01-19 | ノビミューン エスアー | 抗tlr4抗体およびその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1736172A1 (en) | 2006-12-27 |
JPWO2005084707A1 (ja) | 2007-11-29 |
CN1964741A (zh) | 2007-05-16 |
EP1736172A4 (en) | 2009-08-12 |
US20070136828A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11680263B2 (en) | Micro-RNAS and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
Quintana et al. | Lack of GPR88 enhances medium spiny neuron activity and alters motor-and cue-dependent behaviors | |
Krus et al. | Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy | |
Smith et al. | Sigma 1 receptor: A novel therapeutic target in retinal disease | |
McConoughey et al. | Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease | |
Gallardo et al. | An α2-Na/K ATPase/α-adducin complex in astrocytes triggers non–cell autonomous neurodegeneration | |
ES2632212T3 (es) | miR-135 y composiciones que lo comprenden para el tratamiento de afecciones médicas asociadas con la serotonina | |
Abumaria et al. | Effect of chronic citalopram on serotonin-related and stress-regulated genes in the dorsal raphe nucleus of the rat | |
Bandtlow et al. | Increased expression of Nogo‐A in hippocampal neurons of patients with temporal lobe epilepsy | |
US20120328629A1 (en) | Therapeutic Applications Targeting SARM1 | |
Zimmer et al. | Chronic activation of anti‐oxidant pathways and iron accumulation in epileptogenic malformations | |
Steinlein | Ion channel mutations in neuronal diseases: a genetics perspective | |
WO2005084707A1 (ja) | うつ病、不安神経症、薬物依存症、およびこれらに類似した精神疾患治療のための有機カチオントランスポーターoct3関連分子の利用法 | |
US20230046305A1 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
Stavrou et al. | CMT1A current gene therapy approaches and promising biomarkers | |
Kim et al. | Baiap3 regulates depressive behaviors in mice via attenuating dense core vesicle trafficking in subsets of prefrontal cortex neurons | |
Han et al. | SVCT2–mediated ascorbic acid uptake buffers stress responses via DNA hydroxymethylation reprogramming of S100 calcium-binding protein A4 gene | |
Riad et al. | Unchanged density of 5-HT1A autoreceptors on the plasma membrane of nucleus raphe dorsalis neurons in rats chronically treated with fluoxetine | |
Baby et al. | Differential expression of utrophin‐A and‐B promoters in the central nervous system (CNS) of normal and dystrophic mdx mice | |
US20140107104A1 (en) | Combination medicine for treatment of depression | |
CN115006534A (zh) | 钾离子通道Kir4.1抑制剂治疗抑郁症的用途和药物组合物 | |
Rohn et al. | Intranasal delivery of shRNA to knockdown the 5HT-2A receptor enhances memory and alleviates anxiety | |
Zhang et al. | A novel antidepressant acting via allosteric inhibition of GluN2D-incorporated NMDA receptors at GABAergic interneurons | |
Stepanova | Effects of CDNF in experimental models of Huntington’s disease | |
Tan | The role of Fragile X Mental Retardation Protein in Parkinson’s disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510650 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005719492 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580014743.3 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005719492 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007136828 Country of ref document: US Ref document number: 10592154 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10592154 Country of ref document: US |